Reproductive Medicine Center, The Affiliated Drum Tower Hospital of Nanjing University School of Medicine, Nanjing, China.
State Key Laboratory of Pharmaceutical Biotechnology and MOE Key Laboratory of Model Animals for Disease Study, Model Animal Research Center at Medical School of Nanjing University, Nanjing, China.
Front Immunol. 2022 Aug 26;13:960348. doi: 10.3389/fimmu.2022.960348. eCollection 2022.
Rapid advances in high throughput sequencing have substantially expedited the identification and diagnosis of inborn errors of immunity (IEI). Correction of faulty genes in the hematopoietic stem cells can potentially provide cures for the majority of these monogenic immune disorders. Given the clinical efficacies of vector-based gene therapies already established for certain groups of IEI, the recently emerged genome editing technologies promise to bring safer and more versatile treatment options. Here, we review the latest development in genome editing technologies, focusing on the state-of-the-art tools with improved precision and safety profiles. We subsequently summarize the recent preclinical applications of genome editing tools in IEI models, and discuss the major challenges and future perspectives of such treatment modalities. Continued explorations of precise genome editing for IEI treatment shall move us closer toward curing these unfortunate rare diseases.
高通量测序的快速发展极大地加速了先天性免疫缺陷(IEI)的鉴定和诊断。纠正造血干细胞中错误的基因可能为大多数单基因免疫疾病提供治愈方法。鉴于已经为某些组别的 IEI 建立了基于载体的基因治疗的临床疗效,最近出现的基因组编辑技术有望带来更安全、更通用的治疗选择。在这里,我们回顾了基因组编辑技术的最新发展,重点介绍了具有更高精度和安全性的最新工具。随后,我们总结了基因组编辑工具在 IEI 模型中的最新临床前应用,并讨论了这种治疗方式的主要挑战和未来前景。对 IEI 治疗的精确基因组编辑的持续探索将使我们更接近治愈这些不幸的罕见疾病。